BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25572783)

  • 1. Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.
    Porta C; Giglione P; Liguigli W; Paglino C
    Future Oncol; 2015; 11(1):39-50. PubMed ID: 25572783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.
    Kim KB; Chesney J; Robinson D; Gardner H; Shi MM; Kirkwood JM
    Clin Cancer Res; 2011 Dec; 17(23):7451-61. PubMed ID: 21976540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
    Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
    Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.
    Escudier B; Grünwald V; Ravaud A; Ou YC; Castellano D; Lin CC; Gschwend JE; Harzstark A; Beall S; Pirotta N; Squires M; Shi M; Angevin E
    Clin Cancer Res; 2014 Jun; 20(11):3012-22. PubMed ID: 24691021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.
    Dubbelman AC; Upthagrove A; Beijnen JH; Marchetti S; Tan E; Krone K; Anand S; Schellens JH
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):653-63. PubMed ID: 23010851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer.
    Lim SM; Chung WY; Nam KH; Kang SW; Lim JY; Kim HG; Shin SH; Sun JM; Kim SG; Kim JH; Kang CW; Kim HR; Cho BC
    Eur J Cancer; 2015 Aug; 51(12):1588-95. PubMed ID: 26070683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.
    Sarantopoulos J; Goel S; Chung V; Munster P; Pant S; Patel MR; Infante J; Tawbi H; Becerra C; Bruce J; Kabbinavar F; Lockhart AC; Tan E; Yang S; Carlson G; Scott JW; Sharma S
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):921-927. PubMed ID: 27681579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.
    de Weger VA; Goel S; von Moos R; Schellens JHM; Mach N; Tan E; Anand S; Scott JW; Lassen U
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):73-80. PubMed ID: 29101463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib.
    Wang X; Kay A; Anak O; Angevin E; Escudier B; Zhou W; Feng Y; Dugan M; Schran H
    J Clin Pharmacol; 2013 Jan; 53(1):14-20. PubMed ID: 23400739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.
    Schäfer N; Gielen GH; Kebir S; Wieland A; Till A; Mack F; Schaub C; Tzaridis T; Reinartz R; Niessen M; Fimmers R; Simon M; Coch C; Fuhrmann C; Herrlinger U; Scheffler B; Glas M
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1581-9. PubMed ID: 27100354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
    Kim HR; Kang HN; Shim HS; Kim EY; Kim J; Kim DJ; Lee JG; Lee CY; Hong MH; Kim SM; Kim H; Pyo KH; Yun MR; Park HJ; Han JY; Youn HA; Ahn MJ; Paik S; Kim TM; Cho BC
    Ann Oncol; 2017 Jun; 28(6):1250-1259. PubMed ID: 28460066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
    Milowsky MI; Dittrich C; Durán I; Jagdev S; Millard FE; Sweeney CJ; Bajorin D; Cerbone L; Quinn DI; Stadler WM; Rosenberg JE; Lochheed M; Sen P; Squires M; Shi M; Sternberg CN
    Eur J Cancer; 2014 Dec; 50(18):3145-52. PubMed ID: 25457633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).
    Infante JR; Ramanathan RK; George D; Tan E; Quinlan M; Liu A; Scott JW; Sharma S
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):729-37. PubMed ID: 25648347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [FGF/FGFR blockade: New insights in endometrial cancer].
    Flippot R; Vignot S
    Bull Cancer; 2015 Dec; 102(12):964-5. PubMed ID: 26617116
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors.
    Sharma S; Britten CD; Mortimer J; Kulkarni S; Quinlan M; Liu A; Scott JW; George D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):867-74. PubMed ID: 25193431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.
    Bello E; Colella G; Scarlato V; Oliva P; Berndt A; Valbusa G; Serra SC; D'Incalci M; Cavalletti E; Giavazzi R; Damia G; Camboni G
    Cancer Res; 2011 Feb; 71(4):1396-405. PubMed ID: 21212416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
    Konecny GE; Finkler N; Garcia AA; Lorusso D; Lee PS; Rocconi RP; Fong PC; Squires M; Mishra K; Upalawanna A; Wang Y; Kristeleit R
    Lancet Oncol; 2015 Jun; 16(6):686-94. PubMed ID: 25981814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.
    Mazzola CR; Siddiqui KM; Billia M; Chin J
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1553-62. PubMed ID: 25284004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trial.
    Quintela-Fandino M; Bueno MJ; Lombardia L; Gil M; Gonzalez-Martin A; Marquez R; Bratos R; Guerra J; Tan E; Lopez A; Colomer R; Salazar R
    Mol Oncol; 2014 Dec; 8(8):1719-28. PubMed ID: 25103625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.